Randomized, placebo-controlled, phase II trial of EGFR and COX-2 inhibition in advanced non-small cell lung cancer

被引：0
|
作者：
Reckamp, K. L.
Koczywas, M.
Cristea, M. C.
Dowell, J.
Gardner, B.
Milne, G.
Rad, S. Fouladi
Figlin, R. A.
Elashoff, R.
Dubinett, S. M.
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Vanderbilt Univ, Nashville, TN 37235 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps337
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS337
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer
    Kim, Chul
    Liu, Stephen V.
    Subramaniam, Deepa Suresh
    Giaccone, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.
    Zhang, Li
    Shi, Meiqi
    Huang, Cheng
    Liu, Xiaoqing
    Xiong, Jian Ping
    Chen, Gongyan
    Liu, Wei
    Liu, Wenchao
    Zhang, Yiping
    Li, Kai
    Yu, Hao
    Jiang, Haoyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer
    Weitz, JJ
    Marschke, RF
    Sloan, JA
    Grill, JP
    Jett, JR
    Knost, JA
    Hatfield, AK
    Zenk, DW
    Bate, WW
    Schaefer, PL
    LUNG CANCER, 2000, 28 (02) : 157 - 162
  • [34] Randomized phase II trial of irinotecan combined with paclitaxel or gemcitabine in untreated advanced non-small cell lung cancer
    Kinoshita, A.
    Fukuda, M.
    Nagashima, S.
    Fukuda, M.
    Takatani, H.
    Nakano, H.
    Nakamura, Y.
    Oka, M.
    Soda, H.
    Kohno, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 382 - 382
  • [35] MODULATION OF THE CYCLOOXYGENASE PATHWAY IS ASSOCIATED WITH EFFICACY IN A RANDOMIZED PHASE II TRIAL OF ERLOTINIB AND CELECOXIB OR PLACEBO IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Fishbein, Michael C.
    Gardner, Brian
    Milne, Ginder L.
    Koczywas, Marianna
    Cristea, Mihaela
    Dowell, Jonathan E.
    Wang, Hejing
    Figlin, Robert A.
    Elashoff, Robert M.
    Dubinett, Steven M.
    Reckamp, Karen L.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1094 - S1094
  • [36] Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer
    Reckamp, Karen L.
    Koczywas, Marianna
    Cristea, Mihaela C.
    Dowell, Jonathan E.
    Wang, He-Jing
    Gardner, Brian K.
    Milne, Ginger L.
    Figlin, Robert A.
    Fishbein, Michael C.
    Elashoff, Robert M.
    Dubinett, Steven M.
    CANCER, 2015, 121 (18) : 3298 - 3306
  • [37] A phase II of gemcitabine in advanced non-small cell lung cancer
    Koynov, K
    Tzekova, V
    Mincheva, N
    Scherer, A
    Krejcy, K
    3RD INTERNATIONAL CONGRESS ON LUNG CANCER, 1998, : 231 - 234
  • [38] Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial
    Masotti, A
    Zannini, G
    Gentile, A
    Morandini, G
    LUNG CANCER, 2002, 36 (01) : 99 - 103
  • [39] Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer
    Grunberg, SM
    Dugan, MC
    Greenblatt, MS
    Ospina, DJ
    Valentine, JW
    CANCER INVESTIGATION, 2005, 23 (05) : 392 - 398
  • [40] Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer
    Shepherd, FA
    Cormier, Y
    Burkes, R
    Evans, WK
    Goss, G
    Klimo, P
    Feld, R
    Taylor, M
    SEMINARS IN ONCOLOGY, 1997, 24 (03) : 827 - 830
12345